HA

Houman Ashrafian

Executive Vice President, Head of Research and Development

Greater London, England

Investor
VC

Invests in

Stages:

Series A
Seed

Sectors:

BioTech
London

Locations:

London

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Medicine

Education

Investments

Therini Bio

Series A

Total Funding: $62M

Quell Therapeutics

Series B

Total Funding: $160M

Mestag Therapeutics

Seed

Total Funding: $11M

Alchemab Therapeutics

Series A

Total Funding: $83M

Catamaran Bio

Series A

Total Funding: $47M

Enara Bio

Series A

Total Funding: $18M

Sitryx Therapeutics

Series A

Total Funding: $30M

Work Experience

Sanofi

2023

  • Executive Vice President, Head of Research and Development

    2023

Weatherden

2016

  • Chairman Of The Board

    2016

    Weatherden is a leading early clinical development company with a unique model providing partners with rapid, expert, high-quality drug development solutions. Facilitated by global relationships with external experts in all therapeutic areas, Weatherden’s experience extends to all aspects of translational drug discovery and development.

University of Oxford

2014

  • Head of Experimental Therapeutics - Radcliffe Department of Medicine

    2014

Oxford University Hospitals NHS Foundation Trust

2011

  • Honorary Consultant Cardiologist / Co-lead inherited cardiac conditions service

    2011

Mestag Therapeutics

2020 - 2023

  • Chairman Of The Board

    2020 - 2023

Catamaran Bio

2020 - 2023

  • Director

    2020 - 2023

Alchemab Therapeutics Ltd

2019 - 2023

  • Chairman Of The Board

    2019 - 2023

Karus Therapeutics Limited

2018 - 2023

  • Director

    2018 - 2023

Dementia Discovery Fund

2018 - 2023

  • Investment Advisor

    2018 - 2023

SV Health Investors

2016 - 2023

  • Managing Partner

    2018 - 2023

  • Partner

    2017 - 2018

  • Venture Partner

    2016 - 2017